BCM
NTLA icon

Bayesian Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Bayesian Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,600
Closed -$221K – 721
2025
Q2 		$221K Buy
+23,600
New +$194K 0.04% 442
2024
Q3 		– Sell
-30,401
Closed -$680K – 937
2024
Q2 		$680K Buy
30,401
+19,400
+176% +$462K 0.08% 302
2024
Q1 		$303K Buy
+11,001
New +$306K 0.03% 551
2023
Q2 		– Sell
-8,200
Closed -$306K – 981
2023
Q1 		$306K Buy
+8,200
New +$322K 0.04% 502
2022
Q2 		– Sell
-4,146
Closed -$301K – 985
2022
Q1 		$301K Buy
+4,146
New +$351K 0.04% 520
2020
Q2 		– Sell
-10,800
Closed -$132K – 693
2020
Q1 		$132K Buy
+10,800
New +$145K 0.03% 645

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's NTLA Position: Q3 2025 in Review

Bayesian Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 23,600 shares — an estimated $221K sold.

Bayesian Capital Management first reported a position in NTLA in Q1 2020 and held it in 6 quarters. The position peaked at $680K in Q2 2024. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Bayesian Capital Management reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 23,600 Intellia Therapeutics shares in Q3 2025, an estimated $221K.
  • Bayesian Capital Management first reported a position in Intellia Therapeutics in Q1 2020 and held it in 6 quarters.
  • Bayesian Capital Management's Intellia Therapeutics position peaked at $680K in Q2 2024.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.